A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...

A new four-drug combination is highly effective and safe in patients with newly diagnosed multiple myeloma, according to data ...

During a live event, Konstantinos Sdrimas, MD, asked participants what community oncologists should consider when referring ...

A potential cure for a rare type of blood cancer is currently being used to treat 150 patients at various healthcare centers ...

Johnson & Johnson has won the support of an FDA expert panel in its bid to make Darzalex the first treatment for an early ...

In separate live virtual events, Sarah A. Holstein, MD, PhD, and Shashank Cingam, MD, discuss options for a patient with ...

At COMy 2025, researchers highlighted barriers to EMA-approved CAR T-cell therapy access due to age, comorbidities, and ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

New research from COMy 2025 reveals a high rate of infections among people with relapsed or refractory multiple myeloma ...

The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval for the use of GSK’s Blenrep (belantamab ...

Cambridge life science company CellCentric has raised $120 million Series C financing to advance its fight against an ...

EMA’s human medicine committee recommends approval of GSK’s Blenrep combinations in relapsed/refractory multiple myeloma: London, UK Monday, May 26, 2025, 10:00 Hrs [IST] GSK ...